Wall Street Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History

Wall Street Associates’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-6,455	Closed	-$724K	–	265
2015 Q4	$724K	Sell	6,455 -200	-3%	-$20K	0.2%	166
2015 Q3	$641K	Buy	+6,655	New	+$762K	0.12%	198
2014 Q3	–	Sell	-8,700	Closed	-$391K	–	330
2014 Q2	$391K	Sell	8,700 -400	-4%	-$16.5K	0.03%	285
2014 Q1	$445K	Buy	+9,100	New	+$468K	0.04%	273

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wall Street Associates's RARE Position: Q1 2016 in Review

Wall Street Associates sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2016, closing a stake of 6,455 shares — an estimated $724K sold.

Wall Street Associates first reported a position in RARE in Q1 2014 and held it in 4 quarters. The position peaked at $724K in Q4 2015. 161 funds tracked by Wall St. Rank hold RARE as of Q1 2016.

Wall Street Associates reported no remaining Ultragenyx Pharmaceutical position as of Q1 2016 after selling out during the quarter.
Wall Street Associates sold 6,455 Ultragenyx Pharmaceutical shares in Q1 2016, an estimated $724K.
Wall Street Associates first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 4 quarters.
Wall Street Associates's Ultragenyx Pharmaceutical position peaked at $724K in Q4 2015.
161 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2016.

Based on Wall Street Associates's 13F filing for Q1 2016, filed 13 May 2016.